Hyon Choi
0000-0002-2862-0442
20 papers found
Refreshing results…
What Drives the Contemporary Black–White Racial Disparities in Gout in the US? Impact of Social Determinants of Health
Lowering Serum Urate With Urate‐Lowering Therapy to Target and Incident Fracture Among People With Gout
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study
The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care
Hypouricemia and Mortality Risk in the US General Population
Assessing the Causal Relationships between Insulin Resistance and Hyperuricemia and Gout Using Bidirectional Mendelian Randomization
COVID‐19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study
Lifetime Allergy Symptoms in IgG4‐Related Disease: A Case‐Control Study
Effects of Low-Fat, Mediterranean, or Low-Carbohydrate Weight Loss Diets on Serum Urate and Cardiometabolic Risk Factors: A Secondary Analysis of the Dietary Intervention Randomized Controlled Trial (DIRECT)
Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’
Hydroxychloroquine and Mortality Among Patients with Systemic Lupus Erythematosus in the General Population
Increasing Operational Capacity and Reducing Costs of Rituximab Administration: A Costing Analysis
Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid
The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease
Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia
Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study
Reply
Missing publications? Search for publications with a matching author name.